US FDA approves Edwards' Evoque system for major heart valve disease

February 7, 2024 Other Health

This is a preview of subscriber content

Subscribe now to continue reading.

Edwards Lifesciences' EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive FDA approval for tricuspid regurgitation. …

Subscribe now to continue reading.

Latest Video

New Stories

Vaccine confidence slips as Australians grow more concerned about access to healthcare
October 20, 2025 - - Latest News
NZ's Pharmac proposes new rules to manage 'Options for Investment' list
October 20, 2025 - - Latest News
Monash scientists crack genetic ‘code’ behind RNA splicing, opening door to to new therapies
October 20, 2025 - - Australian Biotech
Radiopharm secures funding to accelerate radiopharmaceutical pipeline as data show strong momentum
October 20, 2025 - - Australian Biotech
Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome
October 20, 2025 - - Australian Biotech
Biogen earns fourth 'Great Place to Work' certification, strengthening culture of inclusion
October 20, 2025 - - Latest News
Algorae partners with Cadila Pharmaceuticals to launch therapies in Australia and New Zealand
October 20, 2025 - - Latest News

US FDA approves Edwards' Evoque system for major heart valve disease

This is a preview of subscriber content

Latest Video

Most Read

An exceptional outcome that must not become an exception

BMS says September outcome could set a new policy benchmark for access

Trump announces third MFN deal with a focus on fertility drug costs and expanding IVF access

Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer

New combination therapy sets landmark survival benchmark in bladder cancer treatment

New Stories

Vaccine confidence slips as Australians grow more concerned about access to healthcare

NZ's Pharmac proposes new rules to manage 'Options for Investment' list

Monash scientists crack genetic ‘code’ behind RNA splicing, opening door to to new therapies

Radiopharm secures funding to accelerate radiopharmaceutical pipeline as data show strong momentum

Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome

Biogen earns fourth 'Great Place to Work' certification, strengthening culture of inclusion

Algorae partners with Cadila Pharmaceuticals to launch therapies in Australia and New Zealand

Sign In

US FDA approves Edwards' Evoque system for major heart valve disease

This is a preview of subscriber content

Latest Video

Most Read

An exceptional outcome that must not become an exception

BMS says September outcome could set a new policy benchmark for access

Trump announces third MFN deal with a focus on fertility drug costs and expanding IVF access

Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer

New combination therapy sets landmark survival benchmark in bladder cancer treatment

Follow Us

New Stories

Vaccine confidence slips as Australians grow more concerned about access to healthcare

NZ's Pharmac proposes new rules to manage 'Options for Investment' list

Monash scientists crack genetic ‘code’ behind RNA splicing, opening door to to new therapies

Radiopharm secures funding to accelerate radiopharmaceutical pipeline as data show strong momentum

Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome

Biogen earns fourth 'Great Place to Work' certification, strengthening culture of inclusion

Algorae partners with Cadila Pharmaceuticals to launch therapies in Australia and New Zealand